H1‐antihistamine‐refractory chronic spontaneous urticaria: it's worse than we thought – first results of the multicenter real‐life <scp>AWARE</scp> study
Marcus Maurer(Humboldt-Universität zu Berlin), Nadine Chapman‐Rothe(Novartis (Switzerland)), Uwe Hillen(University of Duisburg-Essen), Nicola Wagner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Andrea Bauer(University Hospital Carl Gustav Carus), Undine Lippert(Städtisches Klinikum Dessau), Petra Staubach(Johannes Gutenberg University Mainz), Grit Richter‐Huhn(Fabmatics (Germany)), Thilo Jakob(Justus-Liebig-Universität Gießen), N. Behnke, Anke Schwinn(Kernkraftwerk Gundremmingen), Amir S. Yazdi(Universitätsklinikum Aachen), Kamel Chaouche(Galderma (Switzerland)), M. Pawlak(Institute for Bioprocessing and Analytical Measurement Techniques), Ulrike Raap(Carl von Ossietzky Universität Oldenburg), Franziska Ruëff(LMU Klinikum), Vera Mahler(Paul Ehrlich Institut)
Cited by 126
Related Papers
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
|New England Journal of Medicine|2013|1.1k